|Bid||1.5600 x 1100|
|Ask||1.5900 x 2900|
|Day's Range||1.5800 - 1.7100|
|52 Week Range||1.3200 - 3.4300|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.
NEW YORK, NY / ACCESSWIRE / November 9, 2020 / Marker Therapeutics, Inc.